文献速递认知障碍与痴呆

生物标志物确诊的非典型阿尔茨海默病表型接受抗淀粉样蛋白治疗的资格分析

Eligibility for Anti-Amyloid Therapies in Patients With Biomarker-Confirmed Atypical Alzheimer Disease Phenotypes.
PubMed 文献 · Neurology · 2026-08-05

该回顾性研究纳入Mayo Clinic 184例生物标志物确诊的非典型AD患者,应用CLARITY-AD、TRAILBLAZER-ALZ2试验标准及lecanemab/donanemab适用标准评估治疗资格。结果显示70%-85%患者不符合治疗标准,主要因MMSE认知阈值排除(占排除原因的50%-67%),各表型间排除原因相似。

要点

  • 非典型AD患者中70%-85%不符合抗淀粉样蛋白治疗试验入选标准。
  • 床旁认知阈值(MMSE)是主要排除原因,占排除的50%-67%。
  • 影像学排除占22%-27%,中重度痴呆严重度阈值排除占19%-23%。

核心结论

  • 大多数非典型AD患者不符合抗淀粉样蛋白治疗资格,主要因MMSE-based排除而非认知功能测量。
  • 各非典型表型间治疗资格率大致相似。

研究设计与样本

  • 回顾性资格分析,纳入Mayo Clinic 184例生物标志物确诊的非典型AD患者(61.4%女性)。
  • 表型分布:PCA 98例(53.3%)、lvPPA 42例(22.8%)、dAD 37例(20.1%)、CBS-AD 7例(3.8%)。
  • 在初次临床评估时应用CLARITY-AD和TRAILBLAZER-ALZ2试验标准及lecanemab/donanemab适用标准评估理论资格。

主要发现

  • lvPPA发病年龄最老(中位发病63.1岁,就诊66.9岁),dAD最年轻(发病55.1岁,就诊57.3岁),组间差异p=0.039。
  • 功能损害因表型而异(p=0.005):lvPPA更多在MCI/极轻度阶段诊断(CDR 0.5,71.4%),PCA和dAD更多表现为轻度痴呆。
  • MMSE评分组间差异显著(p=0.036):PCA和lvPPA中位21分,低于CBS-AD中位27分。
  • 从症状出现到诊断的时间无差异(p=0.634)。
  • 82%患者为早期症状性疾病(全局CDR 0.5-1)。

关键数值与推荐

  • 依据所应用资格框架,70%-85%患者不符合治疗标准。
  • 床旁认知阈值是主要排除原因,占排除的50%-67%。
  • 影像学排除占22%-27%,严重度阈值(中重度痴呆)排除占19%-23%。

临床怎么用

  • 对非典型AD表型患者评估抗淀粉样蛋白治疗时,需注意MMSE阈值可能过度排除早期症状患者。
  • 非典型AD各表型间排除原因相似,提示需针对表型敏感的分期和患者选择标准。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND AND OBJECTIVES: Clinical trials of anti-amyloid therapies (AATs) for Alzheimer disease (AD) primarily enrolled patients with mildly symptomatic, amnestic predominant presentations. The applicability of eligibility criteria to atypical AD phenotypes, including posterior cortical atrophy (PCA), logopenic variant primary progressive aphasia (lvPPA), dysexecutive AD (dAD), and corticobasal syndrome because of AD (CBS-AD), is unknown. METHODS: We conducted a retrospective eligibility analysis of patients with atypical AD evaluated at Mayo Clinic. Theoretical eligibility for AAT was assessed at initial clinical evaluation by applying inclusion and exclusion criteria from landmark clinical trials (Study to Confirm Safety and Efficacy of Lecanemab in Participants With Early Alzheimer's Disease [CLARITY-AD] and the Study of LY3002813 (Donanemab) in Participants With Early Symptomatic Alzheimer's Disease [TRAILBLAZER-ALZ2]) and appropriate use criteria for lecanemab and donanemab. Eligibility percentages and reasons for exclusion were compared across phenotypes. RESULTS: The cohort included 184 patients (61.4% female) with biomarker-confirmed atypical AD: PCA (n = 98, 53.3%), lvPPA (n = 42, 22.8%), dAD (n = 37, 20.1%), and CBS-AD (n = 7, 3.8%). Age at onset (p = 0.039) and presentation (p < 0.001) differed, with patients with lvPPA oldest (median age at onset, presentation: 63.1, 66.9 years) and patients with dAD youngest (onset, presentation: 55.1, 57.3). Functional impairment differed by phenotype (p = 0.005), with lvPPA more often diagnosed at the mild cognitive impairment/very mild stage (Clinical Dementia Rating [CDR] 0.5; 71.4%), whereas PCA and dAD more frequently presented with mild dementia, although time from symptom onset to diagnosis did not differ (p = 0.634). Mini-Mental State Examination (MMSE) scores differed (p = 0.036), with lower scores in PCA and lvPPA (median 21 and 21, respectively) compared with CBS-AD (median 27). Depending on the eligibility framework applied, 70%-85% of patients would not meet treatment criteria. Bedside cognitive thresholds were the primary drivers of ineligibility (50%-67% of exclusions), despite most patients having early symptomatic disease (global CDR 0.5-1; 82%). Imaging-based exclusions (22%-27%) and severity thresholds (moderate or severe dementia, 19%-23%) were also frequent. Reasons for ineligibility were similar across phenotypes. DISCUSSION: Most patients with atypical AD would not meet eligibility criteria for AAT, typically because of MMSE-based exclusion rather than measures of cognitive function. Eligibility rates are broadly similar across atypical phenotypes. These findings highlight the need for phenotype-sensitive staging and patient selection for treatment in atypical AD.

来源:Neurology,查看原文。版权归原作者所有。

引用

  1. Shir D, Corriveau-Lecavalier N, Jones DT, et al. Eligibility for Anti-Amyloid Therapies in Patients With Biomarker-Confirmed Atypical Alzheimer Disease Phenotypes. Neurology. 2026. PMID: 42555876. doi:10.1212/WNL.0000000000218347

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。